Latest Hotspot

Tango Therapeutics receives FDA approval for TNG348, a new USP1 inhibitor targeting BRCA1/2-mutant and other HRD+ cancers

11 September 2023
3 min read

Tango Therapeutics, a biotech company focused on precision cancer medicines, has received FDA clearance for its IND application for TNG348, a new USP1 inhibitor designed to treat BRCA1/2 mutant and other HRD+ cancers.

👇Please click on the image below to directly access the latest data (R&D Status | Core Patent | Clinical Trial | Approval status in Global countries) of this drug.

"The FDA's approval to begin the TNG348 phase 1/2 clinical study marks a significant milestone in the development of an innovative treatment that has the potential to effectively address a considerable number of ovarian, prostate, and breast cancers. Our plan is to initiate the TNG348 clinical trial in the first half of 2024," stated Barbara Weber, MD, President and CEO of Tango Therapeutics.

Previous studies have shown that USP1 inhibition impedes DNA repair through a mechanism distinct from PARP inhibitors. TNG348 has shown activity in xenografts that have both primary and acquired resistance to PARP inhibitors.

Additionally, preclinical data demonstrates that USP1 has a synergistic effect with PARP inhibitors in xenograft models that are naïve to PARP inhibitor therapy. These findings suggest that TNG348 may provide benefits to patients who have progressed on a PARP inhibitor or can be used in combination with single-agent PARP inhibitor therapy," added Barbara Weber.

The phase 1/2 clinical trial will evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of TNG348 as a standalone treatment and in combination with olaparib, a PARP inhibitor, in patients with BRCA1/2-mutant and other HRD+ cancers. HRD+ cancers, which include BRCA1/2 mutations, are responsible for approximately 50% of ovarian cancers, 25% of breast cancers, 10% of prostate cancers, and 5% of pancreatic cancers..

👇Please click on the picture link below for free registration or login directly if you have freemium accounts, you can browse the latest research progress on drugs , indications, organizations, clinical trials, clinical results, and drug patents related to this target.

According to the data provided by the Synapse Database, As of September 11, 2023, there are 13 investigational drugs for the USP1 target, including 4 applicable indications,14 R&D institutions involved, with related clinical trials reaching 3and as many as 511 patents.

The evaluation of the USP1 target showcases a competitive environment with several companies actively engaged in research and development activities. InSilico Medicine Hong Kong Ltd. stands out by having the most extensive portfolio of drugs in Phase 1 and Preclinical stages, signifying substantial progress in R&D. The indications targeted by these drugs include Solid Tumors, Advanced Malignant Solid Neoplasm, Neoplasms, and HRD positive cancer, with the highest number of drugs found in the Phase 1 and Preclinical stages. On the whole, the USP1 target displays promising potential for development and ongoing research in the pharmaceutical industry.

图形用户界面, 文本, 应用程序

描述已自动生成

Glycopyrrolate: Detailed Review of its Transformative R&D Success, Mechanism of Action
Drug Insights
5 min read
Glycopyrrolate: Detailed Review of its Transformative R&D Success, Mechanism of Action
11 September 2023
This article summarized the latest R&D progress of Glycopyrrolate, the Mechanism of Action for Glycopyrrolate, and the drug target R&D trends for Glycopyrrolate.
Read →
Cidara Therapeutics has announced that Janssen has elected to move forward under their license agreement for novel drug-Fc conjugates targeting influenza
Latest Hotspot
3 min read
Cidara Therapeutics has announced that Janssen has elected to move forward under their license agreement for novel drug-Fc conjugates targeting influenza
11 September 2023
Biotech company Cidara Therapeutics is developing drug-Fc conjugate immunotherapies for serious diseases. Janssen Pharmaceuticals, a Johnson & Johnson subsidiary, has given Cidara a go-ahead for CD388 (JNJ-0953), a universal prevention solution for influenza A and B.
Read →
Etodolac Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
Drug Insights
4 min read
Etodolac Unveiled: A Detailed Overview of its Revolutionary R&D Breakthroughs
11 September 2023
This article summarized the latest R&D progress of Etodolac, the Mechanism of Action for Etodolac, and the drug target R&D trends for Etodolac.
Read →
BTK inhibitors, a field with promising prospects
BTK inhibitors, a field with promising prospects
11 September 2023
BTK inhibitors can regulate the functions of various immune cells that are crucial to innate and adaptive immune responses.
Read →
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.